Develops vaccines for hepatitis and influenza diseases.
Dec 2025Revenue $386M/yrExpenses $876M/yr
Fell below break-even Dec 2022Cash runway over 10 years from Dec 2025
Figures by year
When will Sinovac Biotech be profitable again?
Its expenses passed its revenue in Dec 2022. In the 12 months to Dec 2025, revenue was $386M and expenses $876M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $386M | $876M | −$490M |
| Dec 2024 | $361M | $867M | −$506M |
| Dec 2023 | $470M | $1.18B | −$714M |
| Dec 2022 | $1.47B | $1.98B | −$509M |
| Dec 2021 | $19.4B | $1.75B | $17.6B |
| Dec 2020 | $511M | $295M | $216M |
| Dec 2019 | $246M | $177M | $68.6M |
| Dec 2018 | $230M | $184M | $45.3M |
| Dec 2017 | $174M | $129M | $45.4M |
| Dec 2016 | $72.4M | $71.9M | $504K |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.